Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert I. Haddad(Dana-Farber Cancer Institute), Anne O’Neill(Dana-Farber Cancer Institute), Guilherme Rabinowits(Dana-Farber Cancer Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Fadlo R. Khuri(Emory University), Douglas R. Adkins(Washington University in St. Louis), Joseph I. Clark(Loyola University Chicago), Nicholas J. Sarlis(Sanofi (United States)), Jochen H. Lorch(Dana-Farber Cancer Institute), Jonathan J. Beitler(Emory University), Sewanti Limaye(Dana-Farber Cancer Institute), Sarah Riley(Dana-Farber Cancer Institute), Marshall R. Posner(Icahn School of Medicine at Mount Sinai)
The Lancet Oncology
February 12, 2013
Cited by 744

Abstract


Related Papers

No related papers found

Powered by citation graph analysis